Add office photos
Premium Employer
Mankind Pharma
3.9
based on 2.5k Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Mankind Pharma
Company Summary
Mankind Pharma is one of the Indian leading pharmaceutical companies and changes the pharma industry. They provide world-class medications at affordable prices.
Overall Rating
3.9/5
based on 2.5k reviews
On-Par with
industry average
Highly rated for
Salary
Work Policy
Work from office
72% employees reported
Monday to Saturday
68% employees reported
Strict timing
53% employees reported
Within city
40% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
159 employees reported
Health insurance
131 employees reported
Office cab/shuttle
57 employees reported
Cafeteria
42 employees reported
View all benefits
About Mankind Pharma
Founded in1995 (30 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersNew Delhi, Delhi, India
Office Locations
Websitemankindpharma.com
Primary Industry
Other Industries
View in video summary
Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 17,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC, and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel, and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries, and CIS countries.
Mission: To be able to provide cost-effective, innovation based superior quality pharmaceutical products that improve the lives of the patients.
Vision: To be an innovative and research focused healthcare company, most admired for its Quality, Affordability and Accessibility.
Mankind Pharma Ratings
based on 2.5k reviews
Overall Rating
3.9/5
How AmbitionBox ratings work?
5
1.3k
4
568
3
296
2
146
1
237
Category Ratings
3.8
Salary
3.7
Skill development
3.6
Company culture
3.6
Job security
3.6
Work-life balance
3.5
Promotions
3.5
Work satisfaction
Mankind Pharma is rated 3.9 out of 5 stars on AmbitionBox, based on 2.5k company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Mankind Pharma
based on 2.3k reviews
3.7
Rated by 134 Women
Rated 3.7 for Job security and 3.5 for Work-life balance
3.9
Rated by 2.2k Men
Rated 3.9 for Salary and 3.7 for Skill development
Work Policy at Mankind Pharma
based on 359 reviews in last 6 months
Work from office
72%
Hybrid
21%
Permanent work from home
7%
Mankind Pharma Reviews
Top mentions in Mankind Pharma Reviews
+ 5 more
Compare Mankind Pharma with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 3.9/5 based on 2.5k reviews | 4.0/5 based on 7k reviews | 4.1/5 based on 6.2k reviews | 4.1/5 based on 7.1k reviews |
Highly Rated for | Salary | Skill development Company culture Work-life balance | Skill development Company culture Work-life balance | Skill development Salary Work-life balance |
Critically Rated for | No critically rated category | Promotions | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 72% employees reported | Work from office 75% employees reported | Work from office 85% employees reported | Work from office 74% employees reported |
Rating by Women Employees | 3.7 Good rated by 134 women | 4.0 Good rated by 785 women | 4.0 Good rated by 374 women | 4.0 Good rated by 708 women |
Rating by Men Employees | 3.9 Good rated by 2.2k men | 4.1 Good rated by 5.9k men | 4.2 Good rated by 5.5k men | 4.1 Good rated by 6k men |
Job security | 3.6 Good | 3.6 Good | 3.7 Good | 3.7 Good |
View more
Mankind Pharma Salaries
Mankind Pharma salaries have received with an average score of 3.8 out of 5 by 2.5k employees.
Officer
(367 salaries)
Unlock
₹2.1 L/yr - ₹6.5 L/yr
Research Associate
(331 salaries)
Unlock
₹3 L/yr - ₹6.5 L/yr
Research Scientist
(282 salaries)
Unlock
₹3.6 L/yr - ₹10.2 L/yr
Senior Officer
(232 salaries)
Unlock
₹3.6 L/yr - ₹8.1 L/yr
Medical Representative
(230 salaries)
Unlock
₹1.4 L/yr - ₹7.7 L/yr
Area Sales Manager
(172 salaries)
Unlock
₹3.5 L/yr - ₹11 L/yr
Senior Research Scientist
(150 salaries)
Unlock
₹6 L/yr - ₹14.9 L/yr
Deputy Manager
(113 salaries)
Unlock
₹8.2 L/yr - ₹20.5 L/yr
Regional Sales Manager
(91 salaries)
Unlock
₹7.6 L/yr - ₹21.8 L/yr
Area Manager
(79 salaries)
Unlock
₹4.2 L/yr - ₹10 L/yr
Mankind Pharma Interview Questions
Interview questions by designation
Top Mankind Pharma interview questions and answers
Get interview-ready with top interview questions
Mankind Pharma Jobs
Popular Designations Mankind Pharma Hires for
Popular Skills Mankind Pharma Hires for
Current Openings
Mankind Pharma News
View all
Share Market Highlights: Sensex, Nifty end lower as IT, auto stocks weigh; tariff uncertainty looms
- Both Sensex and Nifty gained over 5% in FY25, driven by foreign inflows and stock purchases, with volatility due to tariff risks and earnings concerns.
- IndusInd Bank, M&M, HCL Tech, Maruti, and Infosys were among top losers, while Kotak Bank, ICICI Bank, Tata Motors gained.
- Foreign investors withdrew $15.57 billion for the fiscal year, marking the second-highest outflow ever despite a late rally in the market.
- Broad market weakness seen with 2,501 stocks declining, 428 hitting 52-week lows, and 354 reaching lower circuit on the BSE.
- IREDA signed facility agreement for raising External Commercial Borrowing from SBI, Tokyo Branch, and received work orders worth ₹1,385 crore.
- ASK Asset & Wealth Management Group received SEBI approval for its mutual fund venture.
- National Stock Exchange of India (NSE) and National Securities Depository Limited (NSDL) hosted a Mega RISA seminar to enhance financial literacy and fraud prevention.
- Asian markets opened lower on Trump's tariff threats, with focus on cost escalations and uncertainties in India's auto parts industry.
- India expects another rate cut by RBI, aims to double foreign individual investment limits in listed companies, and plans import duty cuts.
- Monthly Economic Review highlights robust economic growth, stable inflation, growing foreign investments, and positive labour market indicators for India.
- Stock recommendations include buying Mankind Pharma with expected uptrend, and intraday trading guide provides insights for Nifty futures and popular stocks.
HinduBusinessLine | 28 Mar, 2025
Stock Market Live Updates 28 March 2025: Stock to buy today: Mankind Pharma (₹2,463.10)
- The Monthly Economic Review for February 2025 by the ministry emphasized the role of domestic private sector capital formation in driving economic growth in FY26, supported by fiscal measures and accommodative policies.
- India's economy is projected to grow between 6.3 and 6.8 percent in FY26, with inflation expected to remain benign due to favorable food prices.
- The review highlighted the strong economic performance in the latter half of FY25, driven by agricultural and service sector growth, with real GDP estimated to have grown by 6.2 percent in Q3 FY25.
- India's fiscal management remains on track, with a focus on debt consolidation, welfare, and growth initiatives outlined in the Union Budget 2025-26.
- Despite mixed trends in trade performance, India's exports have shown softer growth in FY25, offset by a robust services trade surplus.
- Labour market indicators reflect stability with a decline in urban unemployment rate and positive sentiment towards hiring.
- Foreign investments, although experiencing a decline, are expected to be bolstered by India's capital market resilience and policy reforms.
- The finance ministry reiterated confidence in India's macroeconomic fundamentals to navigate external risks and maintain steady growth in the upcoming fiscal year.
- Various companies have shared positive updates related to expansions, collaborations, new branches, contracts, orders, and investments across sectors.
- Additionally, some companies announced neutral activities such as resignations, credit rating revisions, approvals, and financial strategies.
HinduBusinessLine | 28 Mar, 2025
Mankind Pharma Launches Generic Version Of Empagliflozin Diabetes Medication
- Mankind Pharma has launched a generic version of Empagliflozin, a diabetes medication, in India following the expiration of Boehringer Ingelheim's patent for the drug.
- The generic version is available under the brand names Empaglyde, Empagreat, and Dynaduo, in various strengths (10 mg to 25 mg).
- The launch aims to increase accessibility and affordability, with prices starting at Rs 5.49 for the 10 mg variant and Rs 9.90 for the 25 mg variant.
- Other companies, including Glenmark and Alkem Laboratories, have also introduced generic versions of Empagliflozin in India.
Bloomberg Quint | 12 Mar, 2025
Share Market Highlights 25 February 2025: Sensex, Nifty end flat with a positive bias; Bharti Airtel, M&M lead gains
- Zaggle, a Hyderabad-based software-as-a-service company, will provide comprehensive services for the citizen card and implement the Visitor Management System in GIFT City.
- GIFTCL and Zaggle have entered into a five-year agreement with possible extensions to enhance security and streamline access within GIFT City.
- Axis Finance is undergoing a strategic review with a potential valuation of $900 million to $1 billion, as disclosed by unidentified sources.
- Companies like Max Healthcare, Mankind, and Ashok Leyland witnessed stock gains, whereas Petronet LNG and Delhivery faced losses.
- Tata Capital, with an AUM of ₹1,58,479 crore as of March 2024, is issuing shares worth ₹1,504 crore on a rights basis, with an IPO size expected to be around ₹15,000 crore.
- Camlin Fine Sciences acquires a majority stake in French natural ingredients company Vinpai S.A. to enhance its product range and capabilities.
- Dodo Payments secures $1.1 million in a pre-seed funding round led by Antler, 9Unicorns, and Venture Catalysts, aimed at simplifying international payments for businesses.
- AI adoption in energy companies for predictive maintenance and personalized customer engagement is growing, with GenAI playing a crucial role in enhancing core operations.
- A new environmentally friendly 3-wheeled vehicle, MOBILI SWAP, aims to reduce operating costs and improve efficiency in the transport sector with interchangeable batteries.
- Former President Ranjan Bargotra re-joins Crayons Advertising as Executive Director, bringing strategic expansion plans and extensive industry experience.
HinduBusinessLine | 25 Feb, 2025
Pet Food Brand Dogsee Chew Raises $8 Mn To Scale Global Operations
- Bengaluru-based pet food brand Dogsee Chew has raised $8 million in a Series B funding round led by Ektha.com, with participation from Shivanssh Holdings and Poddar Family office.
- The funding will be used to expand manufacturing capabilities and establish a stronger presence in international markets, particularly the US and Canada.
- Dogsee Chew is known for its vegetarian treats made from Himalayan cheese and aims to become the largest Himalayan chew manufacturer globally.
- The company has already secured previous investments from Mankind Pharma, Sixth Sense Ventures, and has a strong global presence in over 30 countries.
Inc42 | 20 Feb, 2025
MSCI Rejig: Hyundai India Only Addition In February Review; IndusInd Bank, Zomato Weights To Rise
- Hyundai Motor India, IndusInd Bank, Zomato, Varun Beverages, and Mankind Pharma will have increased weightage in the February MSCI review.
- India's weight in MSCI Global Standard Indexes will rise to 19% from the current 18.8% after the quarterly rejig.
- HDFC Bank holds the highest weightage among Indian stocks in MSCI indexes, followed by Reliance Industries, ICICI Bank, Infosys, and Bharti Airtel.
- MSCI added 19 Indian small-cap stocks and removed an equal number from its indices.
Bloomberg Quint | 12 Feb, 2025
Mankind Pharma Approves Sale Of Entire Stake In Wholly Owned Mahananda Spa And Resorts To Chalet Hotels
- Mankind Pharma has approved the sale of its entire stake in Mahananda Spa and Resorts.
- The sale is to Chalet Hotels for an enterprise value of Rs 530 crore.
- The proceeds will be used to retire part of Mankind Pharma's debts.
- The transaction is expected to be completed by February 28.
Bloomberg Quint | 10 Feb, 2025
Tech Query: What is the outlook for Infosys, Barbeque-Nation Hospitality, Mankind Pharma, Happiest Minds Technologies?
- Infosys: The stock is in an uptrend and has been consolidating between ₹1,700 and ₹2,000. Strong support is at ₹1,800-₹1,700. If above support, the outlook remains bullish and a break above ₹2,000 could take the stock to ₹2,300-₹2,400.
- Barbeque-Nation Hospitality: The stock is in a downtrend and has fallen significantly. Resistance is at ₹385 and there is a risk of the stock declining to ₹120. Accumulating at current levels is not advisable. Exit and accept the loss.
- Mankind Pharma: The stock is in a corrective fall and can touch ₹2,250, after which a rally could take it to ₹3,200 over the next couple of years. Selling 20% of the holding and buying at ₹2,300 with a stop-loss at ₹2,140 is recommended.
- Happiest Minds Technologies: The stock is in a downtrend and could fall to ₹610-₹600. Holding on to the stock is not advisable. Consider reinvesting in another stock, such as Mankind Pharma.
HinduBusinessLine | 8 Feb, 2025
Buy, Sell Or Hold: Zomato, RVNL, IRFC, Mankind Pharma, IOC, Bajaj Housing Finance — Ask Profit
- Analysts shared insights on share prices of Zen Technologies, Mankind Pharma, and Natco Pharma.
- RVNL (CMP: Rs 427.65) was advised to hold with strong support at Rs 410–415 levels.
- IRFC (CMP: Rs 141.73) was recommended to hold for one to two weeks with an upside target of 5–8% and a potential to reach Rs 155.
- Mankind Pharma (CMP: Rs 2,477.5) was suggested as a buy with a long-term target of Rs 2,700 in one year.
- Bajaj Housing Finance (CMP: Rs 1,115.87) was advised as a buy, as the numbers were good and there is a good upside potential.
- Zomato (CMP: Rs 222.50) was recommended as a sell, given the high volatility and overall downward trend in the stock.
- Natco Pharma (CMP: Rs 1,171.00) was advised to hold with a target of Rs 1,450 in six-eight months.
- Indian Oil Corp (CMP: Rs 123.64) was suggested to hold with a target of Rs 150–160 in six to 12 months.
- Zen Technologies (CMP: Rs 1,695.30) was recommended to hold for one to two years as a good pick in the long term.
Bloomberg Quint | 29 Jan, 2025
.jpg?w=1200&auto=format%2Ccompress&ogImage=true)
Mankind Pharma, Innovent Biologics Partner To Launch Sintilimab In India
- Mankind Pharma and Innovent Biologics have partnered to launch the immunotherapy drug Sintilimab in the Indian market.
- The collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.
- Sintilimab is co-developed by Innovent and Eli Lilly and is marketed as TYVYT in China.
- Mankind Pharma will file for regulatory approval in India and conduct a phase 3 clinical trial to obtain approval for Sintilimab in the country.
Bloomberg Quint | 26 Dec, 2024
Powered by
Mankind Pharma Subsidiaries
Pathkind Diagnostics Private Limited
4.0
• 458 reviews
Report error
Mankind Pharma Offices
Compare Mankind Pharma with
Zydus Lifesciences
4.1
Sun Pharmaceutical Industries
4.0
Aurobindo Pharma
4.0
Intas Pharmaceuticals
4.1
Hetero
3.9
Viatris
4.2
Glenmark Pharmaceuticals
3.9
Alkem Laboratories
3.9
Ipca Laboratories
3.9
Torrent Pharmaceuticals
3.9
MSN Laboratories
3.7
Akums Drugs & Pharmaceuticals Limited
4.4
Pfizer
4.0
DIVI'S Laboratories
3.7
Piramal Group
3.9
Fresenius Kabi
4.2
Novo Nordisk
4.1
Teva Pharmaceuticals
3.9
Meril
3.7
Sandoz
3.9
Contribute & help others!
You can choose to be anonymous
Companies Similar to Mankind Pharma
Cipla
Manufacturing, Pharma
4.1
• 7.1k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 7k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.1
• 6.2k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6.1k reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.9k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.9k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.5k reviews
Hetero
Healthcare / Pharma, Clinical Research, Healthcare, Pharma
3.9
• 3.4k reviews
Viatris
Manufacturing, Pharma
4.2
• 3.2k reviews
Glenmark Pharmaceuticals
Pharma
3.9
• 2.9k reviews
Alkem Laboratories
Healthcare / Pharma, Biotechnology, Pharma
3.9
• 2.9k reviews
Ipca Laboratories
Pharma
3.9
• 2.9k reviews
Mankind Pharma FAQs
When was Mankind Pharma founded?
Mankind Pharma was founded in 1995. The company has been operating for 30 years primarily in the Pharma sector.
Where is the Mankind Pharma headquarters located?
Mankind Pharma is headquartered in New Delhi, Delhi. It operates in 2 cities such as New Delhi, Gurgaon / Gurugram. To explore all the office locations, visit Mankind Pharma locations.
How many employees does Mankind Pharma have in India?
Mankind Pharma currently has more than 19,000+ employees in India. Marketing & Communication department appears to have the highest employee count in Mankind Pharma based on the number of reviews submitted on AmbitionBox.
Does Mankind Pharma have good work-life balance?
Mankind Pharma has a Work-Life Balance Rating of 3.6 out of 5 based on 2,500+ employee reviews on AmbitionBox. 73% employees rated Mankind Pharma 4 or above, while 27% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Mankind Pharma work-life balance reviews for more details
Is Mankind Pharma good for career growth?
Career growth at Mankind Pharma is rated fairly well, with a promotions and appraisal rating of 3.5. 73% employees rated Mankind Pharma 4 or above, while 27% employees rated it 3 or below on promotions/appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Mankind Pharma promotions/appraisals reviews for more detailed insights.
What are the pros of working in Mankind Pharma?
Working at Mankind Pharma offers several advantages that make it an appealing place for employees. The company is highly rated for salary & benefits, based on 2,500+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
